

Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



FDA ADVISORY No. 2021-2903 1 8 NOV 2021

SUBJECT

Interim Application System in lieu of the Department of Information and Communication Technology (DICT) System Maintenance of License to Operate (LTO) for FDA eServices

This is in relation to the Department of Information and Communication Technology (DICT) Advisory dated 08 November 2021 on system maintenance entitled "Restoration of Government Common Platform (GCP) and New Cloud". As part of the agency's interim measures, the FDA Information and Communication Technology Management Division (ICTMD) established an interim application system to accept and facilitate applications for License-to-Operate. This system will be accessible on 22 November 2021 through https://eservices.fda.gov.ph.

Furthermore, pursuant to Section 9.b.1 of the Republic Act No. 11032 otherwise known as the "Ease of Doing Business and Efficient Government Service Delivery Act of 2018", states that, "in cases where the cause of delay is due to force majeure or natural or man-made disasters, which result to damage or destruction of documents, and/or system failure of the computerized or automatic processing, the prescribed processing times mandated in this Act shall be suspended and appropriate adjustments shall be made"

Following the above policies, all LTO applications shall be given an extension to apply equivalent to the number of days that the system is inaccessible. LTO applications submitted on or before 05 November 2021 and on pending release shall re-apply using this interim application system. Surcharge fees shall not be imposed to those applications affected within the period of system maintenance activity.

In light of the foregoing, all concerned establishments are requested to lodge their LTO application in the abovementioned system. Other authorization applications covered by eServices such as Certificate of Product Registration (CPR) and Compassionate Special Permit (CSP) shall be included in the further development of the interim system. The FDA shall inform all stakeholders once the implementation of this system will cover the rest of the authorizations mentioned above.

This interim system shall only serve as a provisional platform in lieu of the DICT system maintenance.

Dissemination of this advisory to all concerned is hereby requested.

ROLANDO ENRIQUE D. DOMINGO, MD
Director General